These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 32880785)

  • 41. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
    Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
    Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
    Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT
    Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma.
    Pfeifer A; Rusinek D; Żebracka-Gala J; Czarniecka A; Chmielik E; Zembala-Nożyńska E; Wojtaś B; Gielniewski B; Szpak-Ulczok S; Oczko-Wojciechowska M; Krajewska J; Polańska J; Jarząb B
    Genes Chromosomes Cancer; 2019 Aug; 58(8):558-566. PubMed ID: 30664823
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma.
    Zhang T; Lu Y; Ye Q; Zhang M; Zheng L; Yin X; Gavine P; Sun Z; Ji Q; Zhu G; Su X
    Genes Chromosomes Cancer; 2015 Mar; 54(3):168-76. PubMed ID: 25407564
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Shift in Molecular Drivers of Papillary Thyroid Carcinoma Following the 2017 World Health Organization Classification: Characterization of 554 Consecutive Tumors With Emphasis on BRAF-Negative Cases.
    Hang JF; Chen JY; Kuo PC; Lai HF; Lee TL; Tai SK; Kuo CS; Chen HS; Li WS; Li CF
    Mod Pathol; 2023 Sep; 36(9):100242. PubMed ID: 37307878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NTRK-rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China.
    Yin L; Shi C; He X; Qiu Y; Chen H; Chen M; Zhang Z; Chen Y; Zhou Y; Zhang H
    Pathology; 2023 Apr; 55(3):362-374. PubMed ID: 36641377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. How Sensitive is Pan-TRK Immunohistochemistry for Detecting NTRK Fusions in Papillary Thyroid Carcinoma?
    Hang JF; Lee YC
    Mod Pathol; 2023 Jul; 36(7):100222. PubMed ID: 37336120
    [No Abstract]   [Full Text] [Related]  

  • 49. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NTRK-rearranged papillary thyroid carcinoma demonstrates frequent subtle nuclear features and indeterminate cytologic diagnoses.
    Lee YC; Hsu CY; Lai CR; Hang JF
    Cancer Cytopathol; 2022 Feb; 130(2):136-143. PubMed ID: 34644010
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma.
    Brzeziańska E; Pastuszak-Lewandoska D; Lewiński A
    Neuro Endocrinol Lett; 2007 Jun; 28(3):221-9. PubMed ID: 17627253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima.
    Iyama K; Matsuse M; Mitsutake N; Rogounovitch T; Saenko V; Suzuki K; Ashizawa M; Ookouchi C; Suzuki S; Mizunuma H; Fukushima T; Suzuki S; Yamashita S
    Thyroid; 2017 Jun; 27(6):811-818. PubMed ID: 28351223
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    Bastos AU; de Jesus AC; Cerutti JM
    Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NTRK fusions and Trk proteins: what are they and how to test for them.
    Weiss LM; Funari VA
    Hum Pathol; 2021 Jun; 112():59-69. PubMed ID: 33794242
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation.
    Bounacer A; Schlumberger M; Wicker R; Du-Villard JA; Caillou B; Sarasin A; Suárez HG
    Br J Cancer; 2000 Jan; 82(2):308-14. PubMed ID: 10646882
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
    Chu YH; Dias-Santagata D; Farahani AA; Boyraz B; Faquin WC; Nosé V; Sadow PM
    Mod Pathol; 2020 Nov; 33(11):2186-2197. PubMed ID: 32457407
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma.
    Rabban JT; Devine WP; Sangoi AR; Poder L; Alvarez E; Davis JL; Rudzinski E; Garg K; Bean GR
    Histopathology; 2020 Jul; 77(1):100-111. PubMed ID: 31971278
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
    Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gene fusions and oncogenic mutations in MLH1 deficient and BRAFV600E wild-type colorectal cancers.
    Ukkola I; Nummela P; Kero M; Tammio H; Tuominen J; Kairisto V; Kallajoki M; Haglund C; Peltomäki P; Kytölä S; Ristimäki A
    Virchows Arch; 2022 Apr; 480(4):807-817. PubMed ID: 35237889
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.